Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 6, 2007

DSM Pharmaceuticals Incorporates Formulation Development and CTM Manufacturing into Services

  • DSM Pharmaceuticals reports the expansion of its service offerings to include formulation development and clinical trial manufacturing (CTM) for solid dosage form products.

    “This expansion of services will have significant value-added benefits to our customers in terms of reducing cost and accelerating time to market as they will be able to avoid the high cost of tech transfers required for commercial launch by conducting development, CTM, and commercial manufacturing all at DSM’s Greenville, NC, facilities,” remarks Terry Novak, president and business unit director.

    DSM’s pharmaceutical development services will now include preformulation, analytical development, stability studies, formulation and reformulation development, controlled and modified release, controlled substances, clinical trial supply, and regulatory support.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »